HC Wainwright initiated coverage on shares of Kairos Pharma (NYSEAMERICAN:KAPA – Free Report) in a research report report published on Thursday, MarketBeat.com reports. The brokerage issued a buy rating and a $12.00 price objective on the stock.
Other research analysts have also recently issued reports about the stock. Maxim Group initiated coverage on shares of Kairos Pharma in a research report on Thursday, March 27th. They set a “buy” rating and a $4.00 price target on the stock. D. Boral Capital restated a “buy” rating and set a $9.00 target price on shares of Kairos Pharma in a report on Monday, March 31st.
Get Our Latest Stock Analysis on KAPA
Kairos Pharma Price Performance
Kairos Pharma Company Profile
We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma.
See Also
- Five stocks we like better than Kairos Pharma
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Conagra Stock Could Thrive as Tariffs Hit Other Sectors
- Where Do I Find 52-Week Highs and Lows?
- Grocery Costs and Tariffs Now Top of Mind in Everyday Conversations, New Survey Finds
- The Most Important Warren Buffett Stock for Investors: His Own
- Spotify Stock Eyes Double-Digit Upside—Is Now the Time to Buy?
Receive News & Ratings for Kairos Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kairos Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
